XML 118 R105.htm IDEA: XBRL DOCUMENT v3.20.2
Supplementary Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Data (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
 [1]
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Total revenue $ 93.2 $ 164.0 $ 195.1 $ 186.3 $ 215.4 $ 216.6 $ 216.8 $ 202.3 $ 638.6 $ 851.1 $ 743.7
Costs and expenses:                      
Research and development expense 17.4 19.7 18.8 21.3 20.9 21.5 22.4 21.1 77.2 85.9 70.8
Change in the fair value of contingent consideration   (3.4) (0.1) 0.7 (0.3)   1.0 0.4 (2.8) 1.1 (61.2)
Selling, general, and administrative expense 107.4 132.9 134.3 135.5 149.8 140.6 135.2 129.9 510.1 555.5 435.0
Goodwill and intangible asset impairment charges   98.4 1.3           99.7    
Total costs and expenses 161.5 297.7 203.9 207.2 221.0 210.7 210.7 201.1 870.3 843.5 621.8
Operating income (loss) (68.3) (133.7) (8.8) (20.9) (5.6) 5.9 6.1 1.2 (231.7) 7.6 121.9
Other income (expense):                      
Interest income 0.5 0.8 0.8 0.9 0.9 0.7 0.9 0.7 3.0 3.2 1.8
Interest expense (3.1) (2.3) (2.5) (2.9) (3.2) (3.2) (3.4) (2.2) (10.8) (12.0) (3.2)
Other 12.4 4.1 (0.9) 0.6 0.2 (0.1)   1.1 16.2 1.2 (0.4)
Total other income (expense): 9.8 2.6 (2.6) (1.4) (2.1) (2.6) (2.5) (0.4) 8.4 (7.6) (1.8)
Income (loss) before income tax (58.5) (131.1) (11.4) (22.3) (7.7) 3.3 3.6 0.8 (223.3)   120.1
Income tax provision (benefit) (3.0) (15.9) (3.1) (1.7) (3.4) (3.6) 1.0 1.6 (23.7) (4.4) (13.0)
Net income (loss) (55.5) (115.2) (8.3) (20.6) (4.3) 6.9 2.6 (0.8) (199.6) 4.4 133.1
Net loss attributable to non-controlling interest (0.1)       (0.1)     (0.1) (0.1) (0.2) (0.2)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (55.4) $ (115.2) $ (8.3) $ (20.6) $ (4.2) $ 6.9 $ 2.6 $ (0.7) $ (199.5) $ 4.6 $ 133.3
Earnings (loss) per share:                      
Basic $ (0.74) $ (1.55) $ (0.11) $ (0.28) $ (0.06) $ 0.09 $ 0.04 $ (0.01) $ (2.69) $ 0.06 $ 1.92
Diluted $ (0.74) $ (1.55) $ (0.11) $ (0.28) $ (0.06) $ 0.09 $ 0.03 $ (0.01) $ (2.69) $ 0.06 $ 1.85
Weighted average shares outstanding:                      
Basic 74.6 74.5 74.4 73.7 73.4 73.3 74.2 73.0 74,300,000 73,500,000 69,400,000
Diluted 74.6 74.5 74.4 73.7 74.8 74.9 76.5 73.0 74,300,000 76,000,000.0 72,000,000.0
Molecular Diagnostic Testing [Member]                      
Total revenue $ 83.3 $ 150.5 $ 181.1 $ 172.0 $ 196.9 $ 200.5 $ 203.0 $ 189.0 $ 586.9 $ 789.4 $ 690.4
Costs and expenses:                      
Total costs and expenses 32.2 43.1 41.0 41.2 41.6 40.3 44.0 42.3 157.5 168.2 148.7
Pharmaceutical and Clinical Services [Member]                      
Total revenue 9.9 13.5 14.0 14.3 18.5 16.1 13.8 13.3 51.7 61.7 53.3
Costs and expenses:                      
Total costs and expenses $ 4.5 $ 7.0 $ 8.6 $ 8.5 $ 9.0 $ 8.3 $ 8.1 $ 7.4 $ 28.6 $ 32.8 $ 28.5
[1] An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.